Search and Browse
Download
Enter Data
| Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human)) | BDBM127310 (US8791268, 21) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet  | PC cid PC sid UniChem Similars | US Patent | 0.100 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of two substance additions. Initially, the compounds to be tested (10 uM) are pipeted onto the cells and the Ca2+ influx ... | US Patent US8791268 (2014) BindingDB Entry DOI: 10.7270/Q2BV7F9D | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human)) | BDBM127312 (US8791268, 23) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 0.300 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of two substance additions. Initially, the compounds to be tested (10 uM) are pipeted onto the cells and the Ca2+ influx ... | US Patent US8791268 (2014) BindingDB Entry DOI: 10.7270/Q2BV7F9D | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human)) | BDBM127311 (US8791268, 22) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 0.700 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of two substance additions. Initially, the compounds to be tested (10 uM) are pipeted onto the cells and the Ca2+ influx ... | US Patent US8791268 (2014) BindingDB Entry DOI: 10.7270/Q2BV7F9D | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human)) | BDBM127309 (US8791268, 20) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 0.900 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of two substance additions. Initially, the compounds to be tested (10 uM) are pipeted onto the cells and the Ca2+ influx ... | US Patent US8791268 (2014) BindingDB Entry DOI: 10.7270/Q2BV7F9D | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human)) | BDBM127308 (US8791268, 19) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 1.10 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of two substance additions. Initially, the compounds to be tested (10 uM) are pipeted onto the cells and the Ca2+ influx ... | US Patent US8791268 (2014) BindingDB Entry DOI: 10.7270/Q2BV7F9D | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Transient receptor potential cation channel subfamily V member 1 (Rattus norvegicus (rat)) | BDBM127315 (US8791268, 26) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 3.40 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of two substance additions. Initially, the compounds to be tested (10 uM) are pipeted onto the cells and the Ca2+ influx ... | US Patent US8791268 (2014) BindingDB Entry DOI: 10.7270/Q2BV7F9D | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human)) | BDBM127303 (US8791268, 3) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 4.40 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of two substance additions. Initially, the compounds to be tested (10 uM) are pipeted onto the cells and the Ca2+ influx ... | US Patent US8791268 (2014) BindingDB Entry DOI: 10.7270/Q2BV7F9D | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human)) | BDBM127317 (US8791268, 34) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 4.80 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of two substance additions. Initially, the compounds to be tested (10 uM) are pipeted onto the cells and the Ca2+ influx ... | US Patent US8791268 (2014) BindingDB Entry DOI: 10.7270/Q2BV7F9D | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Transient receptor potential cation channel subfamily V member 1 (Rattus norvegicus (rat)) | BDBM127316 (US8791268, 27) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 7.70 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of two substance additions. Initially, the compounds to be tested (10 uM) are pipeted onto the cells and the Ca2+ influx ... | US Patent US8791268 (2014) BindingDB Entry DOI: 10.7270/Q2BV7F9D | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human)) | BDBM127316 (US8791268, 27) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | 7.90 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of two substance additions. Initially, the compounds to be tested (10 uM) are pipeted onto the cells and the Ca2+ influx ... | US Patent US8791268 (2014) BindingDB Entry DOI: 10.7270/Q2BV7F9D | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human)) | BDBM127315 (US8791268, 26) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 9.60 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of two substance additions. Initially, the compounds to be tested (10 uM) are pipeted onto the cells and the Ca2+ influx ... | US Patent US8791268 (2014) BindingDB Entry DOI: 10.7270/Q2BV7F9D | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Transient receptor potential cation channel subfamily V member 1 (Rattus norvegicus (rat)) | BDBM127303 (US8791268, 3) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 16.7 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of two substance additions. Initially, the compounds to be tested (10 uM) are pipeted onto the cells and the Ca2+ influx ... | US Patent US8791268 (2014) BindingDB Entry DOI: 10.7270/Q2BV7F9D | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human)) | BDBM127307 (US8791268, 10) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 24.7 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of two substance additions. Initially, the compounds to be tested (10 uM) are pipeted onto the cells and the Ca2+ influx ... | US Patent US8791268 (2014) BindingDB Entry DOI: 10.7270/Q2BV7F9D | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human)) | BDBM127314 (US8791268, 18) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 25 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of two substance additions. Initially, the compounds to be tested (10 uM) are pipeted onto the cells and the Ca2+ influx ... | US Patent US8791268 (2014) BindingDB Entry DOI: 10.7270/Q2BV7F9D | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human)) | BDBM127306 (US8791268, 7) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 30 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of two substance additions. Initially, the compounds to be tested (10 uM) are pipeted onto the cells and the Ca2+ influx ... | US Patent US8791268 (2014) BindingDB Entry DOI: 10.7270/Q2BV7F9D | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human)) | BDBM127304 (US8791268, 4) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 34 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of two substance additions. Initially, the compounds to be tested (10 uM) are pipeted onto the cells and the Ca2+ influx ... | US Patent US8791268 (2014) BindingDB Entry DOI: 10.7270/Q2BV7F9D | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human)) | BDBM127305 (US8791268, 6) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 38 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of two substance additions. Initially, the compounds to be tested (10 uM) are pipeted onto the cells and the Ca2+ influx ... | US Patent US8791268 (2014) BindingDB Entry DOI: 10.7270/Q2BV7F9D | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Transient receptor potential cation channel subfamily V member 1 (Homo sapiens (Human)) | BDBM127313 (US8791268, 2) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 40.6 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of two substance additions. Initially, the compounds to be tested (10 uM) are pipeted onto the cells and the Ca2+ influx ... | US Patent US8791268 (2014) BindingDB Entry DOI: 10.7270/Q2BV7F9D | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Transient receptor potential cation channel subfamily V member 1 (Rattus norvegicus (rat)) | BDBM127313 (US8791268, 2) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 60.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of two substance additions. Initially, the compounds to be tested (10 uM) are pipeted onto the cells and the Ca2+ influx ... | US Patent US8791268 (2014) BindingDB Entry DOI: 10.7270/Q2BV7F9D | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Transient receptor potential cation channel subfamily V member 1 (Rattus norvegicus (rat)) | BDBM127306 (US8791268, 7) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 63 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of two substance additions. Initially, the compounds to be tested (10 uM) are pipeted onto the cells and the Ca2+ influx ... | US Patent US8791268 (2014) BindingDB Entry DOI: 10.7270/Q2BV7F9D | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Transient receptor potential cation channel subfamily V member 1 (Rattus norvegicus (rat)) | BDBM127304 (US8791268, 4) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 80 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of two substance additions. Initially, the compounds to be tested (10 uM) are pipeted onto the cells and the Ca2+ influx ... | US Patent US8791268 (2014) BindingDB Entry DOI: 10.7270/Q2BV7F9D | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Transient receptor potential cation channel subfamily V member 1 (Rattus norvegicus (rat)) | BDBM127305 (US8791268, 6) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 118 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gruenenthal GmbH US Patent | Assay Description The FLIPR protocol consists of two substance additions. Initially, the compounds to be tested (10 uM) are pipeted onto the cells and the Ca2+ influx ... | US Patent US8791268 (2014) BindingDB Entry DOI: 10.7270/Q2BV7F9D | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
